Janssen Takes Another 'Patent Dance' Step In Remicade Case

Law360, Boston (June 1, 2017, 4:15 PM EDT) -- Janssen Biotech Inc. on Wednesday filed a new lawsuit in Massachusetts federal court over Celltrion's biosimilar for the blockbuster Remicade, yet another step in the so-called patent dance in their long-running dispute. 

The new suit, Janssen told Senior U.S. District Judge Mark Wolf, contains essentially the same allegations they've been fighting over for months. It wasn't even necessary under the Biologics Price Competition and Innovation Act, Janssen said. But defendants Celltrion and Pfizer company Hospira have said that Janssen wouldn't be able to get lost profit damages without filing the new suit.

"Although Janssen strongly disagrees with defendants' position, filing the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!